tirzepatide diabetic retinopathy risk The Link between GLP-1 Drugs and Is Not So Clear | AAO 2024 Early worsening of diabetic retinopathy

1993 Mar;12(2):115-20

Schedule: One subcutaneous injection a week across an 816 week course, with the dose raised in phases

Chronic inflammation is one of the primary barriers to tissue healing in patients with long-standing injuries, and TB-500s anti-inflammatory pathway is part of why it is particularly relevant for patients who have not responded well to other interventions

Ozempic was approved by the US Food and Drug Administration (FDA) as a treatment for type 2 diabetes in 2017, and quickly garnered attention for its unanticipated and striking effect on weight

Dosing typically follows an escalation protocol, beginning at a low dose to improve tolerability before gradually increasing to a target maintenance dose over several weeks or months